Global Cutaneous & Systemic Leishmaniasis Market Size by Drug Class (Pentavalent Antimonials, Antifungal Drugs), by Route of Administration (Oral, Injectable and Topical) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1261438
  • |
  • Publishe Date : September 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

Cutaneous & Systemic Leishmaniasis is a parasitic disease caused by the leishmania parasite. This parasite typically lives in infected sand flies. You can contact leishmaniasis from a bite of an infected sand fly. The sand flies that carry the parasite typically reside in tropical and subtropical environments.

The global cutaneous & systemic leishmaniasis market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. The cutaneous & systemic leishmaniasis market is witnessing significant growth, owing to growing demand for antiparasitic drugs, such as amphotericin B (Ambisome). However, having HIV or AIDS can also complicate the course of leishmaniasis, as well as the treatmen andiIs expected to hamper the growth of the global market.

The global cutaneous & systemic leishmaniasis market is primarily segmented based on different drug class, route of administration and regions. On the basis of drug class, the market is divided into pentavalent antimonials, antifungal drugs and antimicrobial / anti-leishmanial. Depending on Route of Administration, it is categorized into oral, injectable and topical. Region wise, it is analyzed across North America, Europe, Asia-Pacific, South America, and MEA.

On the basis of drug class, the market is split into:
* Pentavalent Antimonials
* Antifungal Drugs
* Antimicrobial / Anti-Leishmanial

On the basis of route of administration, the market is split into:
* Oral
* Injectable
* Topical

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Gilead Sciences, Inc.
* Profounda Pharmaceuticals
* Knight Therapeutics Inc.
* Janssen Global Services, LLC
* Albert David Ltd
* Jubilant Life Sciences Ltd.
* Novartis AG
* Sanofi
* Endo Pharmaceuticals Inc
* Bristol-Myers Squibb Company
* United Biotech Pvt. Ltd.

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, drug class and route of administration market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, drug class and route of administration with qualitative and quantitative information and facts

Target Audience:
* Cutaneous & Systemic Leishmaniasis Treatment Providers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Cutaneous & Systemic Leishmaniasis Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Cutaneous & Systemic Leishmaniasis Market - Porter\'s Five Forces Analysis
4.4. Global Cutaneous & Systemic Leishmaniasis Market - PESTEL Analysis

5. Global Cutaneous & Systemic Leishmaniasis Market, by Drug Class
5.1. Global Cutaneous & Systemic Leishmaniasis Market, Size and Forecast, 2015-2026
5.2. Global Cutaneous & Systemic Leishmaniasis Market, by Pentavalent Antimonials, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Cutaneous & Systemic Leishmaniasis Market, by Antifungal Drugs, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Cutaneous & Systemic Leishmaniasis Market, by Antimicrobial / Anti-leishmanial, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Cutaneous & Systemic Leishmaniasis Market, by Others, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Cutaneous & Systemic Leishmaniasis Market, by Route of Administration
6.1. Global Cutaneous & Systemic Leishmaniasis Market, Size and Forecast, 2015-2026
6.2. Global Cutaneous & Systemic Leishmaniasis Market, by Oral, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Cutaneous & Systemic Leishmaniasis Market, by Injectable, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Cutaneous & Systemic Leishmaniasis Market, by Topical, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026

7. Global Cutaneous & Systemic Leishmaniasis Market, by Region
7.1. Cutaneous & Systemic Leishmaniasis Market Regional Analysis, 2015-2026
7.2. Global Cutaneous & Systemic Leishmaniasis Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.3.1. North America Cutaneous & Systemic Leishmaniasis Market Size and Forecast, 2015-2026
7.3.2. North America Cutaneous & Systemic Leishmaniasis Market by Country, 2015-2026
7.3.2.1. U.S. Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.3.2.2. Canada Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4. Europe Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4.1. Europe Cutaneous & Systemic Leishmaniasis Market Size and Forecast, 2015-2026
7.4.2. Europe Cutaneous & Systemic Leishmaniasis Market by Country, 2015-2026
7.4.2.1. Germany Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4.2.2. France Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4.2.3. Italy Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4.2.4. UK Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4.2.5. Spain Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.4.2.6. Rest of Europe Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.5. Asia Pacific Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.5.1. Asia Pacific Cutaneous & Systemic Leishmaniasis Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Cutaneous & Systemic Leishmaniasis Market by Country, 2015-2026
7.5.2.1. Japan Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.5.2.2. China Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.5.2.3. India Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.6. South America Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.6.1. South America Cutaneous & Systemic Leishmaniasis Market Size and Forecast, 2015-2026
7.6.2. South America Cutaneous & Systemic Leishmaniasis Market by Country, 2015-2026
7.6.2.1. Mexico Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.6.2.2. Brazil Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.6.2.3. Rest of South America Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.7. Middle East & Africa Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.7.1. Middle East & Africa Cutaneous & Systemic Leishmaniasis Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Cutaneous & Systemic Leishmaniasis Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.7.2.2. South Africa Cutaneous & Systemic Leishmaniasis Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Cutaneous & Systemic Leishmaniasis Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2018

9. Company Profiles
9.1. Gilead Sciences, Inc.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Profounda Pharmaceuticals
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Knight Therapeutics Inc.
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Janssen Global Services, LLC
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Albert David Ltd
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. Jubilant Life Sciences Ltd.
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Novartis AG
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Sanofi
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Endo Pharmaceuticals Inc
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Bristol-Myers Squibb Company
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type